The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2023 | Psychosocial experiences in patients with DLBCL receiving CAR-T therapy vs other therapies
Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, comments on the differences observed in the care and psychosocial experiences of patients with diffuse large B-cell lymphoma (DLBCL) treated with CAR-T therapy versus a matched cohort of patients who did not receive CAR-T. Overall, whilst both patient groups did not receive optimal supportive care, patients treated with CAR-T received more support than patients who were not treated with CAR-T. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
